An observational study in Early Breast Cancer, sponsored by Hellenic Cooperative Oncology Group. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Hellenic Cooperative Oncology Group · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group — 3 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Hellenic Cooperative Oncology Group.
Among the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group, this one is the 2nd largest by enrollment of the 14 observational ones that give a count, is one of 3 that started in 1996, is one of 14 observational ones, and was the 18th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →3 of the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group are open now, in 1 country. Recruiting first, the newest first:
Hellenic Cooperative Oncology Group · Sites in Greece
Ages 18+
Hellenic Cooperative Oncology Group · Sites in Greece
Ages 18+ · Women only
Hellenic Cooperative Oncology Group · Sites in Greece
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 3 started in 1996.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,648 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 82 across the 3 interventional studies, 423 across the 14 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hellenic Cooperative Oncology Group is the lead sponsor of 62 studies on the registry; 6 are open to participants now.
2 of the studies in Breast Neoplasms by Hellenic Cooperative Oncology Group that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04985058Hellenic Cooperative Oncology GroupReal-world Data in Patients With Breast Cancer Treated With Abemaciclib | 2026-11-30 |
| NCT07899463Hellenic Cooperative Oncology GroupESR1 Mutations in Metastatic Hormone Receptor-Positive Breast Cancer in the Greek Population | 2027-05-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Breast Neoplasms by Hellenic Cooperative Oncology Group, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Despite the improvements in therapeutic approaches, breast cancer remains the most commonly occurring cancer and leading cause of cancer death in women worldwide. Breast cancer treatment decisions are based mainly on the presence or absence of established prognostic and predictive biomarkers, mainly the hormone receptors, estrogen (ER) and progesterone (PgR), the human epidermal growth factor receptor 2 oncoprotein (HER2) in correlation with ki67 proliferation index.
Currently, PCR-based assays, next-generation sequencing (NGS), and immunohistochemistry (IHC), followed by in situ hybridization (ISH) when needed, are used for biomarker testing. Ιn an effort to overpass technical limitations, human subjectivity which may yield different results between different observers leading to inappropriate treatment and complications that can adversely affect patient quality of life, alternative, cost-effective approaches using AI-based digital pathology analysis of histopathology images has received significant attention last years. Digital pathology uses whole-slide image scanners and combined with artificial intelligence (AI) algorithms intend to improve diagnostic accuracy, enabling rapid patient stratification and optimal treatment regimens, thereby improving patient outcomes. Identification of invasive breast tumors and lymph node metastasis, evaluation of hormonal status, breast cancer grading and mitotic count evaluation, biomarkers identification based on images of the tumor microenvironment have also been enhanced by AI quantitative analysis. AI has promising results so far. More studies are, however, needed in order to overcome obstacles and before it is validated for patient care in the clinical setting.
DL technology has been implemented in clinical pathology in an attempt to automate the way pathologists evaluate hematoxylin and eosin (H/E) stained slides, but also to attain information such as molecular background and protein expression, given that genetic variations could likely be reflected in the morphology of cancer cells, and although not detectable to the human eye, these changes can be recognized by advanced DL algorithms and then correlated with a specific molecular variation or protein expression.
For the purpose of our study, we will use FFPE tumor blocks from patients enrolled in 7 randomized and observational studies conducted by the Hellenic Cooperative Oncology Group (HeCOG) to define via NGS their underlying mutational profile. Subsequently, a DL algorithm will be trained in order to examine if any genetic alterations found in breast cancer could be detected by the DL model in H/E whole section slides, which would suggest that these variants reflect in the morphology of the cancer cells.
Accordingly, we will explore if our algorithm could be trained to identify tumor infiltrating lymphocytes (TILs) by a similar approach using the annotated by our pathologist TILs regions on the H/E slides, as despite their importance, TILs scoring seems to be differentiated among pathologists because of substantial interobserver variation. This fact raises an urgent need for the exploration of novel methods for a more accurate scoring system. Indeed, the International Immuno-Oncology Working Group suggested a computational assessment of TILs based on deep learning models. The evaluation of biomarkers related to TILs, such as CD8, in IHC-stained images has also shown significant potential when DL approaches are used, yielding promising results in no biased TILs evaluation and providing us with valuable details about their distribution and spatial relationships .
Since there are still limitations and things to enhance and more data and parameters need to be incorporated to create more accurate and powerful models, we aim to improve TILs evaluation and therapeutic response prediction in breast cancer, through our deep learning model with the use of H/E whole slide images and digitalized IHC-stained CD8 images for lymphocytes' automatic detection for better quantification of immune response.
Additionally, and apart from ER and PgR IHC-stained slides digitalization, we intend also to digitalize our archive's breast cancer IHC sections stained with HER2 ab, which have already been evaluated by our experienced pathologist, as well as HER2/TOP2A/CEN17 FISH slides. Subsequently, we intend to develop an automated deep learning (DL) - based image analysis algorithm with the ultimate goal of HER2 evaluation with a more accurate than human scoring manner, with the advantage of scoring every cell within a sample specifically to better identify patients with low-level HER2 expression given that T-DXd seems to be efficacious in this patient population . In this way, we will improve diagnostic accuracy by enabling pathologists to review high-resolution digital slides, apply advanced image analysis algorithms, and reduce inter-observer variability, for an accurate HER2 expression in breast cancers.
From 1996 until 2020, 5.320 eligible patients with operable breast cancer were treated, within the context of 3 randomized and 4 observational clinical studies with dds-CT including taxanes and anthracyclines Adjuvant hormonal and radiation treatment were administered, as indicated (Table 1).
All patients have signed a study-specific written informed consent before randomization, consenting for the trial and permitting the use of their biological material for future research purposes. All studies were conducted in accordance with the Declaration of Helsinki.
IHC and FiSH data from patients enrolled in the above randomized phase III trials conducted by the Hellenic Cooperative Oncology Group (HeCOG) will be retrospectively reviewed.
Briefly, tumor material is examined mainly on tissue microarrays (TMA). Although, there is a HER2 assessment from local pathology laboratories, all tumors are re-evaluated centrally for ER, PgR and HER2 according to ASCO/CAP guidelines. Tumors are subtyped with immunohistochemistry (IHC4) for ER, PgR, HER2 and Ki67. FISH is performed for the assessment of HER2 gene status. IHC for EGFR and CK5 is used for the classification of basal-like tumors; the expression of CD8 on TILs is also evaluated. Moreover, we investigate the mutational profile of Greek women with breast cancer, via the application of DNA Next Generation Sequencing (NGS) technologies, relative also to patient outcome. All H\&E and IHC-stained slides will be digitalized for the investigation of the potential of a deep learning-based system for automated biomarker prediction.
Patient demographic, clinicopathological and treatment data are available in all cases.
patients with operable breast cancer treated with dds-CT including taxanes and anthracyclines. Adjuvant hormonal and radiation treatment were administered, as indicated
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Development and Evaluation of an AI-based predictive algorithm
Evaluation of the efficiency of the AI-predictive algorithm, by determining key metrics such as sensitivity and specificity
Time frame: Through study completion, 2 years
Development of an AI-predictive algorithm from H/E and IHC digitalized slides
All H\&E and IHC-stained slides will be digitalized for the investigation of the potential of a deep learning-based system for automated biomarker prediction
Time frame: Through study completion, 2 years
Development of an AI-based algorithm from FISH images
An AI-based algorithm will be developed from FISH images to assess spatial patterns and cell-to-cell heterogeneity in breast cancer samples
Time frame: Through study completion, 2 years
No study locations are listed for this record.
Plan to share: No
Ran from Dec 1996 to primary completion in Jul 2026, 355 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hellenic Cooperative Oncology Group